25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

PHARM (Pharming) Stock Analysis
Buy, Hold or Sell?

Let's analyze Pharming together

I guess you are interested in Pharming Group NV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Pharming’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Pharming’s Price Targets

I'm going to help you getting a better view of Pharming Group NV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Pharming Group NV

I send you an email if I find something interesting about Pharming Group NV.

1. Quick Overview

1.1. Quick analysis of Pharming (30 sec.)










1.2. What can you expect buying and holding a share of Pharming? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€0.31
Expected worth in 1 year
€0.33
How sure are you?
65.0%

+ What do you gain per year?

Total Gains per Share
€0.02
Return On Investment
2.7%

For what price can you sell your share?

Current Price per Share
€0.81
Expected price per share
€0.683 - €0.915
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Pharming (5 min.)




Live pricePrice per Share (EOD)
€0.81
Intrinsic Value Per Share
€0.23 - €0.76
Total Value Per Share
€0.54 - €1.07

2.2. Growth of Pharming (5 min.)




Is Pharming growing?

Current yearPrevious yearGrowGrow %
How rich?$225.7m$203.5m$14.2m6.6%

How much money is Pharming making?

Current yearPrevious yearGrowGrow %
Making money-$4.4m-$5.5m$1m23.7%
Net Profit Margin-7.3%-12.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Pharming (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#233 / 913

Most Revenue
#108 / 913

Most Profit
#386 / 913

Most Efficient
#367 / 913
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Pharming?

Welcome investor! Pharming's management wants to use your money to grow the business. In return you get a share of Pharming.

First you should know what it really means to hold a share of Pharming. And how you can make/lose money.

Speculation

The Price per Share of Pharming is €0.81. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Pharming.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Pharming, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €0.31. Based on the TTM, the Book Value Change Per Share is €0.01 per quarter. Based on the YOY, the Book Value Change Per Share is €0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Pharming.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps0.00-0.2%-0.01-0.8%-0.01-1.0%0.000.4%0.000.0%
Usd Book Value Change Per Share0.010.9%0.010.7%0.010.6%0.011.2%0.010.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.010.9%0.010.7%0.010.6%0.011.2%0.010.9%
Usd Price Per Share0.81-0.96-1.24-1.10-0.87-
Price to Earnings Ratio-132.84--80.36-45.28--18.58--6.77-
Price-to-Total Gains Ratio113.17-44.31-73.91-112.26-22.38-
Price to Book Ratio2.43-3.00-4.16-4.25-9.60-
Price-to-Total Gains Ratio113.17-44.31-73.91-112.26-22.38-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.874719
Number of shares1143
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.010.01
Usd Total Gains Per Share0.010.01
Gains per Quarter (1143 shares)6.6810.68
Gains per Year (1143 shares)26.7142.73
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10271704333
20534408576
3080710128119
40107980171162
501341250214205
601601520256248
701871790299291
802142060342334
902402330385377
1002672600427420

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%6.06.00.050.0%13.07.00.065.0%21.019.00.052.5%22.041.00.034.9%
Book Value Change Per Share3.01.00.075.0%9.03.00.075.0%15.05.00.075.0%26.014.00.065.0%36.023.04.057.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.063.00.0%
Total Gains per Share3.01.00.075.0%9.03.00.075.0%15.05.00.075.0%26.014.00.065.0%36.023.04.057.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Pharming Group NV compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0070.005+23%0.005+42%0.009-23%0.007-6%
Book Value Per Share--0.3080.297+4%0.276+11%0.253+22%0.154+101%
Current Ratio--3.5353.102+14%4.433-20%4.200-16%3.172+11%
Debt To Asset Ratio--0.4690.500-6%0.525-11%0.528-11%0.609-23%
Debt To Equity Ratio--0.8851.007-12%1.107-20%1.134-22%2.663-67%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--323823171.750533292998.998-39%756038809.944-57%668279692.136-52%512363014.181-37%
Eps---0.001-0.006+331%-0.007+426%0.003-145%0.000-2317%
Ev To Ebitda Ratio--infinfnan%4.977+inf%infnan%infnan%
Ev To Sales Ratio--1.1682.087-44%3.834-70%3.345-65%5.710-80%
Free Cash Flow Per Share--0.0130.000+101%-0.008+166%0.007+89%0.007+97%
Free Cash Flow To Equity Per Share--0.011-0.012+206%-0.008+177%0.005+103%0.006+75%
Gross Profit Margin--1.00014.716-93%-6.189+719%2.052-51%1.321-24%
Intrinsic Value_10Y_max--0.760--------
Intrinsic Value_10Y_min--0.230--------
Intrinsic Value_1Y_max--0.033--------
Intrinsic Value_1Y_min--0.003--------
Intrinsic Value_3Y_max--0.133--------
Intrinsic Value_3Y_min--0.027--------
Intrinsic Value_5Y_max--0.272--------
Intrinsic Value_5Y_min--0.069--------
Market Cap549466727.040+7%508765743.750602463346.998-16%783520174.944-35%702066845.075-28%554300115.845-8%
Net Profit Margin---0.014-0.073+430%-0.120+767%0.056-125%-0.222+1507%
Operating Margin----0.0600%-0.0920%0.126-100%-0.0630%
Operating Ratio--1.0361.205-14%1.096-5%0.926+12%1.088-5%
Pb Ratio2.628+7%2.4333.001-19%4.157-41%4.253-43%9.605-75%
Pe Ratio-143.466-8%-132.839-80.360-40%45.284-393%-18.583-86%-6.766-95%
Price Per Share0.810+7%0.7500.888-16%1.150-35%1.017-26%0.808-7%
Price To Free Cash Flow Ratio15.822+7%14.650-0.743+105%18.738-22%50.238-71%23.535-38%
Price To Total Gains Ratio122.220+7%113.16644.307+155%73.909+53%112.260+1%22.379+406%
Quick Ratio--1.9953.293-39%4.174-52%3.898-49%2.713-26%
Return On Assets---0.002-0.010+315%-0.013+437%0.009-126%-0.008+221%
Return On Equity---0.005-0.021+363%-0.027+499%0.021-122%-0.176+3733%
Total Gains Per Share--0.0070.005+23%0.005+42%0.009-23%0.007-6%
Usd Book Value--225789155.021217861004.917+4%203571184.971+11%187976091.952+20%113728183.830+99%
Usd Book Value Change Per Share--0.0070.006+23%0.005+42%0.009-23%0.008-6%
Usd Book Value Per Share--0.3330.321+4%0.299+11%0.274+22%0.166+101%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--349696643.173575903109.618-39%816446310.859-57%721675239.538-52%553300819.014-37%
Usd Eps---0.002-0.007+331%-0.008+426%0.003-145%0.000-2317%
Usd Free Cash Flow--9375881.862-134998.299+101%-6163172.343+166%5188797.614+81%4876705.283+92%
Usd Free Cash Flow Per Share--0.0140.000+101%-0.009+166%0.007+89%0.007+97%
Usd Free Cash Flow To Equity Per Share--0.012-0.012+206%-0.009+177%0.006+103%0.007+75%
Usd Market Cap593369118.530+7%549416126.676650600168.423-16%846123436.922-35%758161985.997-28%598588695.101-8%
Usd Price Per Share0.875+7%0.8100.959-16%1.241-35%1.099-26%0.872-7%
Usd Profit---1033986.972-4455693.858+331%-5513680.527+433%2931439.605-135%130458.175-893%
Usd Revenue--74848056.90371435349.903+5%54679311.032+37%56269676.438+33%39296632.173+90%
Usd Total Gains Per Share--0.0070.006+23%0.005+42%0.009-23%0.008-6%
 EOD+5 -3MRQTTM+27 -9YOY+29 -85Y+16 -2110Y+21 -15

3.3 Fundamental Score

Let's check the fundamental score of Pharming Group NV based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-143.466
Price to Book Ratio (EOD)Between0-12.628
Net Profit Margin (MRQ)Greater than0-0.014
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.995
Current Ratio (MRQ)Greater than13.535
Debt to Asset Ratio (MRQ)Less than10.469
Debt to Equity Ratio (MRQ)Less than10.885
Return on Equity (MRQ)Greater than0.15-0.005
Return on Assets (MRQ)Greater than0.05-0.002
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Pharming Group NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.719
Ma 20Greater thanMa 500.800
Ma 50Greater thanMa 1000.839
Ma 100Greater thanMa 2000.824
OpenGreater thanClose0.820
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Fundamental data was last updated by Penke on 2025-03-19 01:46:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Pharming earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Pharming to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -1.4%Β means thatΒ €-0.01 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Pharming Group NV:

  • The MRQ is -1.4%. The company is making a loss. -1
  • The TTM is -7.3%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ-1.4%TTM-7.3%+5.9%
TTM-7.3%YOY-12.0%+4.7%
TTM-7.3%5Y5.6%-12.9%
5Y5.6%10Y-22.2%+27.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.4%-88.1%+86.7%
TTM-7.3%-190.6%+183.3%
YOY-12.0%-199.6%+187.6%
5Y5.6%-336.0%+341.6%
10Y-22.2%-488.5%+466.3%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Pharming is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Pharming to theΒ Biotechnology industry mean.
  • -0.2% Return on Assets means thatΒ Pharming generatedΒ €0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Pharming Group NV:

  • The MRQ is -0.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.2%TTM-1.0%+0.8%
TTM-1.0%YOY-1.3%+0.3%
TTM-1.0%5Y0.9%-1.9%
5Y0.9%10Y-0.8%+1.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.2%-11.9%+11.7%
TTM-1.0%-11.9%+10.9%
YOY-1.3%-11.6%+10.3%
5Y0.9%-12.7%+13.6%
10Y-0.8%-14.3%+13.5%
4.3.1.3. Return on Equity

Shows how efficient Pharming is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Pharming to theΒ Biotechnology industry mean.
  • -0.5% Return on Equity means Pharming generated €0.00Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Pharming Group NV:

  • The MRQ is -0.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -2.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.5%TTM-2.1%+1.7%
TTM-2.1%YOY-2.7%+0.6%
TTM-2.1%5Y2.1%-4.2%
5Y2.1%10Y-17.6%+19.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.5%-15.6%+15.1%
TTM-2.1%-15.8%+13.7%
YOY-2.7%-14.6%+11.9%
5Y2.1%-18.0%+20.1%
10Y-17.6%-19.2%+1.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Pharming Group NV.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Pharming is operatingΒ .

  • Measures how much profit Pharming makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Pharming to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Pharming Group NV:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-6.0%+6.0%
TTM-6.0%YOY-9.2%+3.2%
TTM-6.0%5Y12.6%-18.6%
5Y12.6%10Y-6.3%+18.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--193.7%+193.7%
TTM-6.0%-296.4%+290.4%
YOY-9.2%-206.9%+197.7%
5Y12.6%-367.9%+380.5%
10Y-6.3%-475.9%+469.6%
4.3.2.2. Operating Ratio

Measures how efficient Pharming is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 1.04 means that the operating costs are €1.04 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Pharming Group NV:

  • The MRQ is 1.036. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.205. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.036TTM1.205-0.169
TTM1.205YOY1.096+0.110
TTM1.2055Y0.926+0.280
5Y0.92610Y1.088-0.162
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0362.025-0.989
TTM1.2053.215-2.010
YOY1.0962.982-1.886
5Y0.9264.689-3.763
10Y1.0886.513-5.425
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Pharming Group NV.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Pharming is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 3.53Β means the company has €3.53 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Pharming Group NV:

  • The MRQ is 3.535. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.102. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.535TTM3.102+0.433
TTM3.102YOY4.433-1.331
TTM3.1025Y4.200-1.098
5Y4.20010Y3.172+1.029
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5353.616-0.081
TTM3.1023.879-0.777
YOY4.4334.483-0.050
5Y4.2005.950-1.750
10Y3.1726.240-3.068
4.4.3.2. Quick Ratio

Measures if Pharming is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Pharming to theΒ Biotechnology industry mean.
  • A Quick Ratio of 2.00Β means the company can pay off €2.00 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Pharming Group NV:

  • The MRQ is 1.995. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.293. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.995TTM3.293-1.297
TTM3.293YOY4.174-0.881
TTM3.2935Y3.898-0.605
5Y3.89810Y2.713+1.184
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9952.966-0.971
TTM3.2933.336-0.043
YOY4.1744.252-0.078
5Y3.8985.921-2.023
10Y2.7136.474-3.761
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Pharming Group NV.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of PharmingΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Pharming to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.47Β means that Pharming assets areΒ financed with 46.9% credit (debt) and the remaining percentage (100% - 46.9%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Pharming Group NV:

  • The MRQ is 0.469. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.500. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.469TTM0.500-0.030
TTM0.500YOY0.525-0.025
TTM0.5005Y0.528-0.028
5Y0.52810Y0.609-0.081
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4690.340+0.129
TTM0.5000.340+0.160
YOY0.5250.312+0.213
5Y0.5280.359+0.169
10Y0.6090.382+0.227
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Pharming is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Pharming to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 88.5% means that company has €0.88 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Pharming Group NV:

  • The MRQ is 0.885. The company is very able to pay all its debts with equity. +2
  • The TTM is 1.007. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ0.885TTM1.007-0.122
TTM1.007YOY1.107-0.100
TTM1.0075Y1.134-0.128
5Y1.13410Y2.663-1.529
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8850.393+0.492
TTM1.0070.428+0.579
YOY1.1070.395+0.712
5Y1.1340.451+0.683
10Y2.6630.493+2.170
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Pharming generates.

  • Above 15 is considered overpriced butΒ always compareΒ Pharming to theΒ Biotechnology industry mean.
  • A PE ratio of -132.84 means the investor is paying €-132.84Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Pharming Group NV:

  • The EOD is -143.466. Based on the earnings, the company is expensive. -2
  • The MRQ is -132.839. Based on the earnings, the company is expensive. -2
  • The TTM is -80.360. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-143.466MRQ-132.839-10.627
MRQ-132.839TTM-80.360-52.479
TTM-80.360YOY45.284-125.644
TTM-80.3605Y-18.583-61.777
5Y-18.58310Y-6.766-11.817
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-143.466-2.074-141.392
MRQ-132.839-2.522-130.317
TTM-80.360-3.216-77.144
YOY45.284-3.300+48.584
5Y-18.583-6.225-12.358
10Y-6.766-6.955+0.189
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Pharming Group NV:

  • The EOD is 15.822. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 14.650. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -0.743. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD15.822MRQ14.650+1.172
MRQ14.650TTM-0.743+15.392
TTM-0.743YOY18.738-19.481
TTM-0.7435Y50.238-50.980
5Y50.23810Y23.535+26.702
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD15.822-2.854+18.676
MRQ14.650-3.511+18.161
TTM-0.743-3.835+3.092
YOY18.738-4.297+23.035
5Y50.238-8.217+58.455
10Y23.535-9.311+32.846
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Pharming is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 2.43 means the investor is paying €2.43Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Pharming Group NV:

  • The EOD is 2.628. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.433. Based on the equity, the company is underpriced. +1
  • The TTM is 3.001. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.628MRQ2.433+0.195
MRQ2.433TTM3.001-0.568
TTM3.001YOY4.157-1.156
TTM3.0015Y4.253-1.251
5Y4.25310Y9.605-5.352
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.6281.874+0.754
MRQ2.4332.120+0.313
TTM3.0012.372+0.629
YOY4.1572.453+1.704
5Y4.2533.811+0.442
10Y9.6054.584+5.021
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets425,514
Total Liabilities199,722
Total Stockholder Equity225,792
 As reported
Total Liabilities 199,722
Total Stockholder Equity+ 225,792
Total Assets = 425,514

Assets

Total Assets425,514
Total Current Assets282,192
Long-term Assets143,322
Total Current Assets
Cash And Cash Equivalents 60,662
Short-term Investments 111,104
Net Receivables 48,199
Inventory 62,227
Total Current Assets  (as reported)282,192
Total Current Assets  (calculated)282,192
+/-0
Long-term Assets
Property Plant Equipment 30,667
Long Term Investments 7,166
Long-term Assets Other 1,548
Long-term Assets  (as reported)143,322
Long-term Assets  (calculated)39,381
+/- 103,941

Liabilities & Shareholders' Equity

Total Current Liabilities79,839
Long-term Liabilities119,883
Total Stockholder Equity225,792
Total Current Liabilities
Short Long Term Debt 3,319
Accounts payable 72,638
Total Current Liabilities  (as reported)79,839
Total Current Liabilities  (calculated)75,957
+/- 3,882
Long-term Liabilities
Long term Debt 92,099
Capital Lease Obligations Min Short Term Debt31,666
Long-term Liabilities  (as reported)119,883
Long-term Liabilities  (calculated)123,765
+/- 3,882
Total Stockholder Equity
Total Stockholder Equity (as reported)225,792
Total Stockholder Equity (calculated)0
+/- 225,792
Other
Capital Stock7,750
Common Stock Shares Outstanding 678,354
Net Debt 34,756
Net Invested Capital 321,210
Net Working Capital 202,353
Property Plant and Equipment Gross 30,667



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-31
> Total Assets 
0
0
0
80,066
82,432
87,869
74,075
49,592
46,405
43,127
37,683
32,006
36,952
0
20,095
22,276
37,634
37,367
32,005
43,370
45,665
55,928
51,724
67,754
58,207
56,260
69,943
63,058
63,209
59,697
54,812
133,338
140,457
145,242
164,331
199,379
210,432
209,697
223,936
245,446
224,106
233,988
241,593
255,634
335,220
356,646
374,932
419,116
408,566
412,023
400,906
350,552
392,798
393,898
382,323
425,797
422,996
429,805
436,467
462,854
441,668
415,928
425,514
425,514415,928441,668462,854436,467429,805422,996425,797382,323393,898392,798350,552400,906412,023408,566419,116374,932356,646335,220255,634241,593233,988224,106245,446223,936209,697210,432199,379164,331145,242140,457133,33854,81259,69763,20963,05869,94356,26058,20767,75451,72455,92845,66543,37032,00537,36737,63422,27620,095036,95232,00637,68343,12746,40549,59274,07587,86982,43280,066000
   > Total Current Assets 
0
0
0
40,934
45,588
54,752
40,056
38,897
33,832
26,785
22,452
17,058
22,066
0
8,652
11,174
25,069
27,204
22,272
33,968
36,673
47,054
43,765
59,758
51,327
48,891
62,631
55,859
55,797
51,529
46,014
65,405
70,641
69,912
86,487
105,875
116,431
121,952
134,264
132,052
114,197
115,081
111,367
119,302
197,325
219,750
232,020
263,632
261,823
251,258
242,193
220,085
250,948
256,980
252,048
277,500
266,056
278,573
291,737
316,342
296,550
270,632
282,192
282,192270,632296,550316,342291,737278,573266,056277,500252,048256,980250,948220,085242,193251,258261,823263,632232,020219,750197,325119,302111,367115,081114,197132,052134,264121,952116,431105,87586,48769,91270,64165,40546,01451,52955,79755,85962,63148,89151,32759,75843,76547,05436,67333,96822,27227,20425,06911,1748,652022,06617,05822,45226,78533,83238,89740,05654,75245,58840,934000
       Cash And Cash Equivalents 
0
0
0
22,814
28,608
39,635
22,897
13,701
20,450
14,339
11,860
4,895
10,535
0
1,886
6,974
23,182
16,977
17,139
23,431
25,581
35,820
29,987
41,569
32,623
27,790
39,216
34,595
31,173
23,820
18,807
33,538
29,235
28,595
45,075
70,371
72,070
75,776
82,531
91,868
73,292
72,638
68,892
74,266
147,610
171,829
181,738
205,486
206,254
188,385
183,308
169,335
189,674
189,964
188,703
207,342
184,780
192,373
54,653
61,741
51,892
47,142
60,662
60,66247,14251,89261,74154,653192,373184,780207,342188,703189,964189,674169,335183,308188,385206,254205,486181,738171,829147,61074,26668,89272,63873,29291,86882,53175,77672,07070,37145,07528,59529,23533,53818,80723,82031,17334,59539,21627,79032,62341,56929,98735,82025,58123,43117,13916,97723,1826,9741,886010,5354,89511,86014,33920,45013,70122,89739,63528,60822,814000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-737
-519
-662
-568
-700
-989
0
0
0
0
0
0
0
0
0
0
0
142,912
151,683
150,078
113,181
111,104
111,104113,181150,078151,683142,91200000000000-989-700-568-662-519-73700000000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
3,277
241
306
329
830
388
0
369
538
859
7,085
606
849
807
1,775
2,115
1,715
2,571
4,774
4,652
3,272
4,394
6,173
6,588
11,975
21,208
21,329
20,283
12,217
17,717
19,395
27,388
18,304
25,585
27,997
29,524
26,277
33,710
29,676
31,049
31,936
32,883
37,568
32,808
26,454
31,445
32,878
28,828
27,619
32,931
33,158
40,521
42,615
38,697
51,119
48,199
48,19951,11938,69742,61540,52133,15832,93127,61928,82832,87831,44526,45432,80837,56832,88331,93631,04929,67633,71026,27729,52427,99725,58518,30427,38819,39517,71712,21720,28321,32921,20811,9756,5886,1734,3943,2724,6524,7742,5711,7152,1151,7758078496067,08585953836903888303293062413,2770000000
       Other Current Assets 
0
0
0
1,994
1,828
1,463
1,912
9,932
584
684
919
2,804
1,161
0
1,298
668
-2,838
247
618
2,008
0
0
0
144
0
0
0
227
0
0
0
974
0
0
0
1,077
0
0
0
1,813
0
0
0
2,279
0
0
0
4,081
-1
830
846
200
222
209
412
213
218
0
212
3,543
0
0
0
0003,5432120218213412209222200846830-14,0810002,2790001,8130001,0770009740002270001440002,008618247-2,8386681,29801,1612,8049196845849,9321,9121,4631,8281,994000
   > Long-term Assets 
0
0
0
39,133
36,844
33,116
34,020
10,694
12,573
16,342
15,231
14,948
14,886
0
11,443
11,102
9,727
10,163
9,733
9,402
8,992
8,873
7,960
7,995
6,880
7,369
7,312
7,199
7,412
8,168
8,798
67,933
69,816
75,330
77,845
93,504
94,001
87,745
89,672
113,394
109,909
118,907
130,227
136,333
137,895
136,896
142,912
155,484
146,743
160,765
158,713
130,467
141,850
136,918
130,275
148,297
156,940
151,232
144,730
146,512
145,118
145,296
143,322
143,322145,296145,118146,512144,730151,232156,940148,297130,275136,918141,850130,467158,713160,765146,743155,484142,912136,896137,895136,333130,227118,907109,909113,39489,67287,74594,00193,50477,84575,33069,81667,9338,7988,1687,4127,1997,3127,3696,8807,9957,9608,8738,9929,4029,73310,1639,72711,10211,443014,88614,94815,23116,34212,57310,69434,02033,11636,84439,133000
       Property Plant Equipment 
0
0
0
7,508
6,976
6,348
7,377
8,913
9,350
13,189
12,416
12,400
12,405
0
9,326
9,427
8,858
8,761
8,906
8,600
8,238
8,169
7,329
6,807
5,836
6,302
6,257
6,189
6,379
6,535
6,629
6,355
6,884
8,127
9,176
9,878
9,826
9,586
9,642
9,611
13,664
17,080
16,151
16,278
15,739
15,781
19,386
21,687
21,881
37,646
37,893
29,262
31,897
29,958
27,782
39,145
40,772
39,346
37,482
33,466
31,862
30,724
30,667
30,66730,72431,86233,46637,48239,34640,77239,14527,78229,95831,89729,26237,89337,64621,88121,68719,38615,78115,73916,27816,15117,08013,6649,6119,6429,5869,8269,8789,1768,1276,8846,3556,6296,5356,3796,1896,2576,3025,8366,8077,3298,1698,2388,6008,9068,7618,8589,4279,326012,40512,40012,41613,1899,3508,9137,3776,3486,9767,508000
       Goodwill 
0
0
0
6,178
5,789
4,784
2,016
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-9,867
0
3,447
-1,438
0
5,905
6,137
3,779
0
5,006
0
0
005,00603,7796,1375,9050-1,4383,4470-9,867000000000000000000000000000000000000000000002,0164,7845,7896,178000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,377
5,517
5,307
5,515
5,616
5,682
5,796
5,722
6,104
8,630
8,787
7,403
11,631
10,776
9,731
9,767
9,650
9,239
10,398
7,681
7,363
7,166
7,1667,3637,68110,3989,2399,6509,7679,73110,77611,6317,4038,7878,6306,1045,7225,7965,6825,6165,5155,3075,5175,37700000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
25,195
23,844
21,770
24,387
1,547
1,580
1,556
1,400
0
1,258
0
0
708
0
0
0
559
0
0
0
945
0
0
0
792
0
0
0
59,610
56,148
55,855
56,735
67,940
56,272
55,843
56,322
59,981
52,062
51,516
67,806
79,318
0
0
0
94,233
0
0
0
83,834
0
72,319
71,561
75,121
69,701
67,276
66,070
71,267
63,293
0
0
0063,29371,26766,07067,27669,70175,12171,56172,319083,83400094,23300079,31867,80651,51652,06259,98156,32255,84356,27267,94056,73555,85556,14859,610000792000945000559000708001,25801,4001,5561,5801,54724,38721,77023,84425,195000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,838
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,743
0
1,748
0
12,002
11,757
12,551
40,529
33,642
32,665
0
35,162
27,620
24,854
22,585
30,815
0
0
18,802
22,488
21,229
19,563
21,594
24,300
30,795
28,823
0
0
0
0
0
0000028,82330,79524,30021,59419,56321,22922,48818,8020030,81522,58524,85427,62035,162032,66533,64240,52912,55111,75712,00201,74802,7430000000000000002,8380000000000000000
> Total Liabilities 
0
0
0
60,992
74,575
74,008
49,632
36,159
34,723
37,213
34,688
33,545
41,694
0
34,360
32,396
45,362
38,145
34,155
36,452
35,885
39,297
31,573
31,464
26,509
24,975
41,163
36,995
39,371
39,500
38,004
104,451
109,531
137,504
157,037
176,822
171,463
162,680
167,959
174,809
146,544
145,882
142,604
138,376
207,699
213,173
214,963
235,389
222,540
213,865
207,375
180,341
198,777
194,228
182,069
221,159
223,653
229,433
226,525
244,073
235,723
194,991
199,722
199,722194,991235,723244,073226,525229,433223,653221,159182,069194,228198,777180,341207,375213,865222,540235,389214,963213,173207,699138,376142,604145,882146,544174,809167,959162,680171,463176,822157,037137,504109,531104,45138,00439,50039,37136,99541,16324,97526,50931,46431,57339,29735,88536,45234,15538,14545,36232,39634,360041,69433,54534,68837,21334,72336,15949,63274,00874,57560,992000
   > Total Current Liabilities 
0
0
0
51,966
66,014
62,727
25,454
12,879
10,719
9,676
9,677
10,544
18,931
0
13,147
11,860
26,279
19,354
14,297
17,848
18,218
22,460
16,765
18,086
15,255
13,976
15,649
14,732
18,550
20,537
20,517
54,034
65,817
39,421
65,908
70,216
72,889
74,428
100,265
94,485
69,928
75,011
98,582
114,130
48,969
49,362
42,858
76,969
73,705
47,838
46,717
41,265
45,151
49,194
46,694
59,698
59,003
64,952
68,058
77,968
207,285
79,937
79,839
79,83979,937207,28577,96868,05864,95259,00359,69846,69449,19445,15141,26546,71747,83873,70576,96942,85849,36248,969114,13098,58275,01169,92894,485100,26574,42872,88970,21665,90839,42165,81754,03420,51720,53718,55014,73215,64913,97615,25518,08616,76522,46018,21817,84814,29719,35426,27911,86013,147018,93110,5449,6779,67610,71912,87925,45462,72766,01451,966000
       Short-term Debt 
0
0
0
39,402
48,689
42,092
15,148
60
0
0
0
1,579
5,536
0
1,207
1,184
13,463
9,326
3,959
1,058
670
644
586
761
329
237
2,270
3,619
4,870
6,195
6,613
27,764
33,581
12,920
20,165
26,663
34,798
40,972
42,049
40,606
39,559
40,486
39,968
53,248
1,813
1,740
2,048
4,008
4,960
4,624
4,517
3,792
4,324
4,120
3,950
5,233
5,749
5,653
5,518
5,440
138,769
6,970
0
06,970138,7695,4405,5185,6535,7495,2333,9504,1204,3243,7924,5174,6244,9604,0082,0481,7401,81353,24839,96840,48639,55940,60642,04940,97234,79826,66320,16512,92033,58127,7646,6136,1954,8703,6192,2702373297615866446701,0583,9599,32613,4631,1841,20705,5361,5790006015,14842,09248,68939,402000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
67,393
65,590
90,494
16,908
21,962
27,945
35,174
35,924
35,235
34,963
33,607
34,432
45,590
0
0
0
1,661
2,607
1,657
1,657
1,657
1,844
1,728
1,627
1,768
1,805
1,797
1,748
1,824
134,889
3,147
3,319
3,3193,147134,8891,8241,7481,7971,8051,7681,6271,7281,8441,6571,6571,6572,6071,66100045,59034,43233,60734,96335,23535,92435,17427,94521,96216,90890,49465,59067,3930000000000000000000000000000000
       Accounts payable 
0
0
0
0
11,280
9,471
0
0
0
0
0
0
0
0
7,560
1,489
5,754
3,556
4,765
5,561
9,791
4,478
7,446
3,579
9,301
9,061
8,979
1,111
10,515
11,340
10,898
5,944
18,040
17,161
19,997
11,313
35,714
30,933
36,216
7,598
29,306
33,471
37,491
5,994
46,993
47,414
40,648
13,491
43,603
43,142
42,147
37,473
40,827
45,074
42,744
54,465
53,254
59,299
62,540
16,022
68,516
72,967
72,638
72,63872,96768,51616,02262,54059,29953,25454,46542,74445,07440,82737,47342,14743,14243,60313,49140,64847,41446,9935,99437,49133,47129,3067,59836,21630,93335,71411,31319,99717,16118,0405,94410,89811,34010,5151,1118,9799,0619,3013,5797,4464,4789,7915,5614,7653,5565,7541,4897,560000000009,47111,2800000
       Other Current Liabilities 
0
0
0
12,564
6,045
5,216
10,307
12,879
10,719
9,676
9,677
8,965
13,395
0
3,411
6,627
4,583
2,393
2,604
8,191
4,731
14,337
5,941
11,071
3,242
2,203
1,917
7,590
664
547
599
19,334
13,258
8,413
24,800
31,275
1,387
1,598
21,070
45,366
165
144
20,249
20,278
163
208
162
25,219
25,142
71
53
1,539
0
3,933
4,031
47,578
5,300
5,180
5,219
56,506
3,596
0
0
003,59656,5065,2195,1805,30047,5784,0313,93301,539537125,14225,21916220816320,27820,24914416545,36621,0701,5981,38731,27524,8008,41313,25819,3345995476647,5901,9172,2033,24211,0715,94114,3374,7318,1912,6042,3934,5836,6273,411013,3958,9659,6779,67610,71912,87910,3075,2166,04512,564000
   > Long-term Liabilities 
0
0
0
9,026
8,561
11,281
24,178
23,280
24,004
27,537
25,011
23,002
22,763
0
21,213
20,536
19,082
18,792
19,858
18,604
17,667
16,837
14,808
13,379
11,254
10,998
25,514
22,263
20,820
18,963
17,487
50,416
43,714
98,083
91,129
106,606
98,575
88,252
67,694
80,324
76,616
70,871
44,022
24,246
158,729
163,812
172,106
158,420
148,834
166,027
160,657
139,076
153,626
145,034
135,375
161,461
164,650
164,481
158,467
166,105
28,438
115,054
119,883
119,883115,05428,438166,105158,467164,481164,650161,461135,375145,034153,626139,076160,657166,027148,834158,420172,106163,812158,72924,24644,02270,87176,61680,32467,69488,25298,575106,60691,12998,08343,71450,41617,48718,96320,82022,26325,51410,99811,25413,37914,80816,83717,66718,60419,85818,79219,08220,53621,213022,76323,00225,01127,53724,00423,28024,17811,2818,5619,026000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,944
6,742
6,541
6,341
29,786
29,586
28,222
16,640
32,788
31,985
32,325
16,222
17,282
18,298
18,298
18,298
173
161
159
333
165
162
152
143
0
0
0
0
0
0
0
0
0000000014315216216533315916117318,29818,29818,29817,28216,22232,32531,98532,78816,64028,22229,58629,7866,3416,5416,7426,9440000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
791
0
0
0
3,588
0
0
0
2,237
0
0
0
4,304
0
0
0
4,443
0
0
0
266
0
0
0
0
0
0
0
0
0
0
0
000000000002660004,4430004,3040002,2370003,5880007910000000000000000000000000000000
> Total Stockholder Equity
0
0
0
19,074
7,858
13,860
16,773
14,449
11,682
5,914
2,995
-1,540
-4,742
0
-14,265
-10,120
-7,727
-778
-2,150
6,918
9,780
16,631
20,152
36,289
31,698
31,285
28,779
26,063
23,838
20,197
16,808
28,887
30,926
7,738
7,294
22,557
38,968
47,017
55,977
70,637
77,562
88,106
98,989
117,258
127,522
143,473
159,968
183,727
186,026
198,158
193,531
170,211
194,021
199,670
200,254
204,638
199,343
200,372
209,942
218,781
205,945
220,937
225,792
225,792220,937205,945218,781209,942200,372199,343204,638200,254199,670194,021170,211193,531198,158186,026183,727159,968143,473127,522117,25898,98988,10677,56270,63755,97747,01738,96822,5577,2947,73830,92628,88716,80820,19723,83826,06328,77931,28531,69836,28920,15216,6319,7806,918-2,150-778-7,727-10,120-14,2650-4,742-1,5402,9955,91411,68214,44916,77313,8607,85819,074000
   Common Stock
0
0
0
110,681
103,708
14,863
19,559
23,208
26,043
26,703
26,627
26,447
29,961
0
11,410
13,347
1,692
2,735
3,102
4,620
5,146
5,531
5,173
4,958
4,419
4,578
4,594
4,504
4,675
4,589
4,629
4,792
5,118
5,536
6,107
6,946
7,418
7,057
7,172
7,109
6,987
7,114
6,885
7,072
7,004
7,172
7,492
7,857
7,183
7,254
7,259
6,425
7,468
7,469
7,482
7,509
7,518
7,540
7,650
7,669
7,681
7,748
0
07,7487,6817,6697,6507,5407,5187,5097,4827,4697,4686,4257,2597,2547,1837,8577,4927,1727,0047,0726,8857,1146,9877,1097,1727,0577,4186,9466,1075,5365,1184,7924,6294,5894,6754,5044,5944,5784,4194,9585,1735,5315,1464,6203,1022,7351,69213,34711,410029,96126,44726,62726,70326,04323,20819,55914,863103,708110,681000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-6,636
0
0
0
-6,796
0
0
0
-7,569
0
0
0
18,706
18,208
18,595
19,388
20,539
20,662
20,700
20,969
44
45
44
47
72
71
73
72
63
43
-700
-494
-1,125
-2,911
-1,270
-985
1,884
1,729
1,998
1,277
4,165
4,144
4,284
4,980
5,339
11,337
14,671
9,864
1,917
-910
-12,607
-24,145
-8,737
-4,906
-6,037
-10,915
-2,057
-4,001
6,390
0
06,390-4,001-2,057-10,915-6,037-4,906-8,737-24,145-12,607-9101,9179,86414,67111,3375,3394,9804,2844,1444,1651,2771,9981,7291,884-985-1,270-2,911-1,125-494-7004363727371724744454420,96920,70020,66220,53919,38818,59518,20818,706000-7,569000-6,796000-6,636000
   Capital Surplus 000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
204,766
-95,850
-1,003
-2,786
241,423
-14,361
-20,789
-23,632
244,389
-34,704
0
313,101
231,866
236,909
243,270
245,885
254,901
272,491
281,216
282,261
282,260
282,385
282,428
281,841
283,396
283,517
283,528
283,538
301,876
308,320
310,907
316,858
370,220
381,042
387,760
391,023
387,525
387,956
389,310
391,151
392,266
394,255
396,033
396,231
396,799
382,438
380,856
390,928
399,850
457,961
458,357
459,450
462,297
463,222
464,363
475,983
478,431
444,498
454,257
0
0454,257444,498478,431475,983464,363463,222462,297459,450458,357457,961399,850390,928380,856382,438396,799396,231396,033394,255392,266391,151389,310387,956387,525391,023387,760381,042370,220316,858310,907308,320301,876283,538283,528283,517283,396281,841282,428282,385282,260282,261281,216272,491254,901245,885243,270236,909231,866313,1010-34,704244,389-23,632-20,789-14,361241,423-2,786-1,003-95,850204,766000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue226,910
Cost of Revenue-33,504
Gross Profit193,406193,406
 
Operating Income (+$)
Gross Profit193,406
Operating Expense-213,788
Operating Income-20,383-20,383
 
Operating Expense (+$)
Research Development60,144
Selling General Administrative80,684
Selling And Marketing Expenses6,817
Operating Expense213,788147,645
 
Net Interest Income (+$)
Interest Income3,663
Interest Expense-5,964
Other Finance Cost-134
Net Interest Income-2,435
 
Pretax Income (+$)
Operating Income-20,383
Net Interest Income-2,435
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-10,843-29,922
EBIT - interestExpense = -26,347
-11,111
-3,793
Interest Expense5,964
Earnings Before Interest and Taxes (EBIT)-20,383-4,879
Earnings Before Interest and Taxes (EBITDA)-10,199
 
After tax Income (+$)
Income Before Tax-10,843
Tax Provision--1,464
Net Income From Continuing Ops-10,548-9,379
Net Income-9,757
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses247,293
Total Other Income/Expenses Net9,5392,435
 

Technical Analysis of Pharming
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Pharming. The general trend of Pharming is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Pharming's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Pharming Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Pharming Group NV.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 0.818 < 0.854 < 0.915.

The bearish price targets are: 0.71 > 0.699 > 0.683.

Know someone who trades $PHARM? Share this with them.πŸ‘‡

Pharming Group NV Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Pharming Group NV. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Pharming Group NV Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Pharming Group NV. The current macd is -0.0086562.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Pharming price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Pharming. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Pharming price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Pharming Group NV Daily Moving Average Convergence/Divergence (MACD) ChartPharming Group NV Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Pharming Group NV. The current adx is 16.54.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Pharming shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Pharming Group NV Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Pharming Group NV. The current sar is 0.75531391.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Pharming Group NV Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Pharming Group NV. The current rsi is 48.72. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Pharming Group NV Daily Relative Strength Index (RSI) ChartPharming Group NV Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Pharming Group NV. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Pharming price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Pharming Group NV Daily Stochastic Oscillator ChartPharming Group NV Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Pharming Group NV. The current cci is 30.47.

Pharming Group NV Daily Commodity Channel Index (CCI) ChartPharming Group NV Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Pharming Group NV. The current cmo is 0.44961177.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Pharming Group NV Daily Chande Momentum Oscillator (CMO) ChartPharming Group NV Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Pharming Group NV. The current willr is -30.55555556.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Pharming is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Pharming Group NV Daily Williams %R ChartPharming Group NV Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Pharming Group NV.

Pharming Group NV Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Pharming Group NV. The current atr is 0.03352784.

Pharming Group NV Daily Average True Range (ATR) ChartPharming Group NV Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Pharming Group NV. The current obv is -76,616,706.

Pharming Group NV Daily On-Balance Volume (OBV) ChartPharming Group NV Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Pharming Group NV. The current mfi is 58.61.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Pharming Group NV Daily Money Flow Index (MFI) ChartPharming Group NV Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Pharming Group NV.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-11-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-22MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-11-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-11-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-03ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-10STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-11ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-12-16MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-30RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-31WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-02-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-06ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-11STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-12MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-27STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Pharming Group NV Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Pharming Group NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.719
Ma 20Greater thanMa 500.800
Ma 50Greater thanMa 1000.839
Ma 100Greater thanMa 2000.824
OpenGreater thanClose0.820
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Pharming with someone you think should read this too:
  • Are you bullish or bearish on Pharming? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Pharming? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Pharming Group NV

I send you an email if I find something interesting about Pharming Group NV.


Comments

How you think about this?

Leave a comment

Stay informed about Pharming Group NV.

Receive notifications about Pharming Group NV in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.